Patents by Inventor Shifeng Pan

Shifeng Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7750021
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: July 6, 2010
    Assignee: IRM LLC
    Inventors: Yuan Mi, Shifeng Pan, Nathanael Schiander Gray, Wenqi Gao, Yi Fan, Tao Jiang
  • Patent number: 7718704
    Abstract: The invention provides a novel class of cyclic oximes of Formula I: wherein A, X, Y, Z, W, R1, R2, R3 and n are as described in the summary of the invention; useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: May 18, 2010
    Assignee: IRM LLC
    Inventors: Shifeng Pan, Wenqi Gao, Nathanael Schiander Gray, Yuan Mi
  • Publication number: 20100029605
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
    Type: Application
    Filed: September 24, 2007
    Publication date: February 4, 2010
    Applicants: Novartis AG
    Inventors: Pamela Albaugh, Gregory S. Chopiuk, Qiang Ding, Shenlin Huang, Zuosheng Liu, Shifeng Pan, Pingda Ren, Xia Wang, Xing Wang, yongping Xie, Chengzhi Zhang, Qiong Zhang, Guobao Zhang, Daniel Poon, Paul Renhowe, Martin Sendzik
  • Patent number: 7638523
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 29, 2009
    Assignees: IRM LLC, Novartis AG
    Inventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
  • Publication number: 20090312308
    Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    Type: Application
    Filed: July 24, 2007
    Publication date: December 17, 2009
    Applicant: IRM LLC
    Inventors: Dai Cheng, Dong Han, Wenqi Gao, Jiqing Jiang, Shifeng Pan, Yongqin Wan, Qihui Jin
  • Publication number: 20090306039
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
    Type: Application
    Filed: July 20, 2007
    Publication date: December 10, 2009
    Inventors: Shifeng Pan, Yi Liu, Yun Feng Xie, Dai Cheng, yongqin Wan, Dong Han, Yang Yang, Wenqi Gao, Jiqing Jiang, Badry Bursulaya, Philip Chamberlain, Donald Karanewsky, Xia Wang
  • Publication number: 20090264649
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: May 29, 2009
    Publication date: October 22, 2009
    Applicants: IRM LLC, Novartis AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
  • Patent number: 7592349
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: September 22, 2009
    Assignees: IRM LLC, Novartis AG
    Inventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
  • Publication number: 20090221547
    Abstract: The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction. This application relates to compounds selected from Formula (Ia), (Ib), (Ic) and (Id).
    Type: Application
    Filed: August 22, 2006
    Publication date: September 3, 2009
    Applicant: IRM LLC
    Inventors: Wenqi Gao, Yongqin Wan, Jiqing Jiang, Yi Fan, Nathanael S. Gray, Shifeng Pan
  • Publication number: 20090203666
    Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    Type: Application
    Filed: May 4, 2007
    Publication date: August 13, 2009
    Applicant: IRM LLC
    Inventors: Wenqi Gao, Jiqing Jiang, Yongqin Wan, Dai Cheng, Dong Han, Xu Wu, Shifeng Pan
  • Patent number: 7572811
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: August 11, 2009
    Assignee: IRM LLC
    Inventors: Shifeng Pan, Thomas Marsilje, Wenshuo Lu, Wenqi Gao, Nathanael Schiander Gray, Yun He, Yahua Liu, Yuan Mi, Yongping Xie
  • Patent number: 7563894
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: July 21, 2009
    Assignees: IRM LLC, Novartis AG
    Inventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
  • Publication number: 20090131400
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Application
    Filed: July 25, 2008
    Publication date: May 21, 2009
    Applicant: IRM LLC
    Inventors: Yuan Mi, Shifeng Pan, Nathanael Schiander Gray, Wenqi Gao, Yi Fan, Tao Jiang
  • Patent number: 7514447
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: April 7, 2009
    Assignees: IRM LLC, Novartis AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiadong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
  • Publication number: 20090036423
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Application
    Filed: February 1, 2008
    Publication date: February 5, 2009
    Inventors: Shifeng Pan, Wenqi Gao, Nathanael S. Gray, Yuan Mi, Yi Fan
  • Publication number: 20090012094
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: October 31, 2007
    Publication date: January 8, 2009
    Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS, AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
  • Patent number: 7462629
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: December 9, 2008
    Assignee: IRM LLC
    Inventors: Shifeng Pan, Nathanael S. Gray, Yuan Mi, Yi Fan, Wenqi Gao
  • Patent number: PP20531
    Abstract: A new Lantana plant named ‘Bant Reda09,’ particularly distinguished by the red flower color, larger flowers, a relatively compact and mounding habit that is well branched, and has dark-green foliage.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: December 8, 2009
    Assignee: Syngenta Crop Protection AG
    Inventor: Shifeng Pan
  • Patent number: PP20555
    Abstract: A new Lantana plant named ‘Bant Pin09,’ particularly distinguished by the purple/pink flower color, larger flowers, good floriferiousness, a relatively compact and mounding habit that is well branched, and has dark-green foliage.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: December 15, 2009
    Assignee: Syngenta Crop Protection AG
    Inventor: Shifeng Pan
  • Patent number: PP20557
    Abstract: A new Lantana plant named ‘Bant Targol,’ particularly distinguished by yellow/orange flower color, medium size flowers, good floriferiousness, sets very few seeds, a flat trailing habit that is well branched, and has dark green foliage.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: December 15, 2009
    Assignee: Syngenta Crop Protection AG
    Inventor: Shifeng Pan